Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PinCell
Milan, Lombardy, Italypincell.it ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PinCell has demonstrated in vivo efficacy for its monoclonal antibody (PC111) in blocking blister formation in skin disease models without immunosuppression; PC111 has Orphan Drug Designation in Pemphigus (EMA), with plans for FDA Orphan/Breakthrough applications. PC111 ameliorates features of SJS/TEN in in vivo models[4][1].
- Therapeutic areas
- Dermatology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
Scinai Immunotherapeutics Ltd. (option agreement to acquire; collaboration on PC111, grant application[4])Sofinnova Partners (seed investor[1])
Beyond the preview
Go deeper on PinCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PinCell.